Daratumumab

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1) . Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].

Product Specifications

CAS Number

[945721-28-8]

Product Name Alternative

Anti-Human CD38, Human Antibody; HuMax-CD38; JNJ-54767414

UNSPSC

12352203

Target

ADC Antibody; CD38

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/daratumumab.html

Purity

99.10

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

[Daratumumab]

Molecular Weight

(145.26 kDa)

References & Citations

[1]Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7 (10) :e1486948. Published 2018 Jul 23.|[2]de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186 (3) :1840-1848.